Undisclosed CD3/HER2 BsAb
/ Biocytogen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
Preclinical syngeneic model and xenograft model for evaluating CD3/HER2 bispecific antibody therapy
(AACR 2025)
- "Additionally, CD3/HER2 BsAb also significantly inhibited the growth of human tumor cells NCI-N87 in a PBMC reconstitution model using B-NDG mice. These results indicate that both models are suitable for the preclinical evaluation of the CD3/HER2 BsAb."
Preclinical • Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1